Background on Company
Novel scientific insights to unlock the full potential of B cell therapeutics
Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases
Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020
Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation for AT-1965
Collaborative team with leadership across all biotech disciplines; premier scientific advisors and leading entrepreneur backers
Financing underway to fund AT-1965 clinical initiation and development
What you will learn from this webinar
How a B cell activation approach differs from other cancer immunotherapy approaches
How clinical data drives value creation in cancer immunotherapy
How AT-1965 is poised to lead the next frontier in cancer immunotherapy
How investment in Akamara will diversify your cancer immunotherapy portfolio
Hemptown USA has generated $17.6 million in revenue for 2019 and closed $23M in funding through 2 capital raises.
What you will learn from this webinar:
About hemp-derived cannabinoids and how Hemptown USA became an established and experienced operator in this emerging industry.
The hemp value chain, and Hemptown USA’s diversified revenue approach.
What is CBG and why it is the next big cannabinoid.
Why Hemptown USA’s production platform and M&A strategy present a unique opportunity for investors.